Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.

Antiviral research - 1 Aug 2011

Furman Phillip A, Murakami Eisuke, Niu Congrong, Lam Angela M, Espiritu Christine, Bansal Shalini, Bao Haiying, Tolstykh Tatiana, Micolochick Steuer Holly, Keilman Meg, Zennou Veronique, Bourne Nigel, Veselenak Ronald L, Chang Wonsuk, Ross Bruce S, Du Jinfa, Otto Michael J, Sofia Michael J

Abstract excerpt

PSI-353661, a phosphoramidate prodrug of 2'-deoxy-2'-fluoro-2'-C-methylguanosine-5'-monophosphate, is a highly active inhibitor of genotype 1a, 1b, and 2a HCV RNA replication in the replicon assay and of genotype 1a and 2a infectious virus replication. PSI-353661 is active against replicons harboring the NS5B S282T or S96T/N142T amino acid alterations that confer decreased susceptibility to nucleoside/tide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Cathepsin A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanylate Kinases

Share to Hep G2 Cells

Share to Lactic Acid

Share to Phenol

Share to Prodrugs

Share to Replicon

Source

Open in PubMed Open full text

Identifiers

PMID: 21600932
DOI: 10.1016/j.antiviral.2011.05.003
PMCID: PMC3135787

Genes

CES1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.PMID 21600932Read ↗

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.Semantic proximity Read ↗

Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.Semantic proximity Read ↗

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.Semantic proximity Read ↗

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.Semantic proximity Read ↗

Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.Semantic proximity Read ↗

2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.Semantic proximity Read ↗

Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor.Semantic proximity Read ↗

Helicase Inhibitors as Specifically Targeted Antiviral Therapy for Hepatitis cSemantic proximity Read ↗

Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.Semantic proximity Read ↗

NS5A--from obscurity to new target for HCV therapy.Semantic proximity Read ↗

Nucleotide Prodrugs for HCV TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.